Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2881-2889

  Ellis, Peter M ^a   Kaiser, Rolf ^b   Zhao, Yihua ^c   Stopfer, Peter ^b   Gyorffy, Steve ^d   Hanna, Nasser ^e  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIBF 1120; HEMOGLOBIN; PEMETREXED;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFUSION; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EPISTAXIS; ESOPHAGUS PAIN; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HUMAN; HYPERTENSION; INSOMNIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RECTUM HEMORRHAGE; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMATES; GUANINE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 77952325749     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2944     Document Type: Article

References (31)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594 (Pubitemid 351720831)
2. Bedano PM, Hanna NH. Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006;1:582-587 (Pubitemid 47181409)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132 (Pubitemid 41058344)
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98 (Pubitemid 34438899)
5. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18
6. Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 2007;13:345-348
7. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312 (Pubitemid 351717519)
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550 (Pubitemid 44917502)
9. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-1234
10. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750 (Pubitemid 350086476)
11. Herbst R, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009;27:Abstract CRA8003.
12. de Boer R, Humblet Y, Wolf J, et al. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 2009;20:486-491
13. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-4277 (Pubitemid 47548567)
14. Hilberg F, Roth GJ, Krssak M, et al. BIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res 2008;68:4774-4782
15. Hilberg F, Brandstetter I. Efficacy of BIBF 1120, a potent triple angio-kinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy. Eur J Cancer 2007;2:S380.
16. Lee CP, Attard G, Poupard L, et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. J Clin Oncol 2005;23:3054.
17. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angio-genesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-319
18. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guide-lines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
19. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597 (Pubitemid 41079796)
20. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007;8:15-27.
21. Ledermann JA, Rustin GJ, Hackshaw A, et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009;27:15s-4.
22. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. Presented at WCLC. San Fransisco (CA): 2009.
23. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191 (Pubitemid 41095154)
24. Scagliotti G vPJ, Reck M, Cupit L, et al. Sorafenib plus carboplatin/ paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. J Thorac Oncol 2008;3:S97.
25. Sweeney CJ, Takimoto CH, Latz JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12:536-542
26. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multi-targeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380
27. Dy GK, Suri A, Reid JM, et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;55:522-530 (Pubitemid 40674627)
28. Stopfer P, Roth W, Mross KB, et al. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Eur J Cancer Supplements 2006;4:26.
29. Camidge DR, Conkling P, Stephenson J, Shapiro D. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:S730.
30. Raymond E, Goldwasser F, Bousquet C, et al. A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaïve hormone refractory prostate cancer patients (HRPC). Eur J Cancer 2007;5:S108.
31. Harter P, Huober J, Pfisterer J, et al. A phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies. J Clin Oncol 2007;25:S153.